) shares jumped over 7% on Jul 11 after it announced that
additional results from the BENEFIT-ALS (Blinded Evaluation of
Neuromuscular Effects and Functional Improvement with Tirasemtiv in
ALS) study on tirasemtiv were presented at the 13th International
Congress on Neuromuscular Diseases in Nice last week.
Tirasemtiv is being developed for the treatment of patients
suffering from amyotrophic lateral sclerosis (ALS). Additional data
revealed that a statistically significant reduction in Slow Vital
Capacity (SVC) decline was observed in the tirasemtiv treatment
group compared to those under placebo across all subgroups of
patients with ALS.
However, the additional results on tirasemtiv might not provide the
much sought after respite for Cytokinetics. The company stated that
it is still evaluating the data from the BENEFIT-ALS study for the
future pathway of the candidate. We remind investors that earlier
in the year, Cytokinetics announced that tirasemtiv failed to meet
its primary endpoint in the BENEFIT-ALS study. The company's shares
nosedived 64.7% after the announcement. (Read:
Cytokinetics' Tirasemtiv Misses Primary
As far as Cytokinetics' pipeline is concerned, the road so far has
been disappointing. Last year, Cytokinetics and
) omecamtiv mecarbil failed to meet its primary endpoint in a phase
II study. The study evaluated the safety, pharmacokinetics,
pharmacodynamics and efficacy of an intravenous formulation of
omecamtiv mecarbil in patients hospitalized with acute heart
Needless to say, Cytokinetics badly needs its pipeline to deliver
in order to drive growth. We expect investor focus to stay on the
company's decision on tirasemtiv's future pathway.
Cytokinetics currently carries a Zacks Rank #1 (Strong Buy). Some
other stocks worth considering include
The Medicines Company
). Both stocks also carry a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
MEDICINES CO (MDCO): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
CYTOKINETCS INC (CYTK): Free Stock Analysis
To read this article on Zacks.com click here.